(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 December 2014 (04.12.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/191737 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *C07D 487/04* (2006.01)
C07D 401/04 (2006.01) *A61K 31/501* (2006.01)
C07D 403/14 (2006.01) *A61K 31/502* (2006.01)
C07D 413/14 (2006.01) *A61K 31/5025* (2006.01)
C07D 417/14 (2006.01) *A61P 35/00* (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:
PCT/GB2014/051623

(22) International Filing Date:
28 May 2014 (28.05.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1309508.8 28 May 2013 (28.05.2013) GB

(71) Applicant: **REDX PHARMA LIMITED** [GB/GB]; 2nd Floor, Biohub, Mereside, Alderley Park, Alderley Edge Cheshire SK10 4TF (GB).

(72) Inventors: **ARMER, Richard**; RedxOncology Ltd, Duncan Building, Royal Liverpool University Hospital, Liverpool Merseyside L69 3GA (GB). **BINGHAM, Matilda**; RedxOncology Ltd, Duncan Building, Royal Liverpool University Hospital, Liverpool Merseyside L69 3GA (GB). **BHAMRA, Inder**; RedxOncology Ltd, Duncan Building, Royal Liverpool University Hospital, Liverpool Merseyside L69 3GA (GB). **MCCARROLL, Andrew**; RedxOncology Ltd, Duncan Building, Royal Liverpool University Hospital, Liverpool Merseyside L69 3GA (GB).

(74) Agent: **HGF LIMITED**; Belgrave Hall, Belgrave Street, Leeds, Yorkshire, LS2 8DD (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2014/191737 A1

(54) Title: HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS



(I)

(57) Abstract: This invention relates to novel compounds of formula (I). The compounds of the invention are hedgehog pathway antagonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) inhibitors. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.